← Eichor
Study identifier: NCT06095466 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology

Condition: Cirrhotic Cardiomyopathy · Cirrhosis, Liver · Cardiac Disease  ·  Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

PhaseN/A
Planned participants150
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Cirrhotic cardiomyopathy is associated with increased risk of complications like hepatorenal syndrome, refractory ascites, impaired response to stressors including sepsis, bleeding or transplantation, poor health related quality of life and increased morbidity and mortality. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre.

This description comes directly from the study's public registry record.

Talk to the study team

Madhumita Premkumar  ·  01722754777  ·  drmadhumitap@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Dr. Madhumita PremkumarSector-12, Chandigarh, IndiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06095466